VistaGen Therapeutics (VTGN) 10K Form and Latest SEC Filings 2026

VistaGen Therapeutics logo
$0.20 +0.01 (+6.12%)
Closing price 04:00 PM Eastern
Extended Trading
$0.20 0.00 (-0.25%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest VistaGen Therapeutics SEC Filings & Recent Activity

VistaGen Therapeutics (NASDAQ:VTGN) has submitted 377+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in VistaGen Therapeutics's financial statements. The most recent filing was a Form 10-Q submitted on November 13, 2026.

8-K
VistaGen Therapeutics Files Current Report on Nov. 13, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
VistaGen Therapeutics Files Quarterly Report on Nov. 13, 2026

The 10-Q contains VistaGen Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

VistaGen Therapeutics SEC Filing History

Browse VistaGen Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

Filing Date
0 Results
DateFilerForm TypeView
11/13/2026 3:08 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2026 3:11 PM
VistaGen Therapeutics (1411685) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/09/2026 7:34 AM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/30/2026 4:24 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/09/2026 4:15 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/25/2026 8:11 AM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/24/2026 6:05 AM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/22/2026 3:22 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2026 4:49 PM
ORBIMED ADVISORS LLC (1055951) Filed by
VistaGen Therapeutics (1411685) Subject
Form SCHEDULE 13G/A
08/14/2026 3:04 PM
Commodore Capital LP (1831942) Filed by
VistaGen Therapeutics (1411685) Subject
Form SCHEDULE 13G/A
08/14/2026 7:40 AM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2026 3:16 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/31/2026 3:10 PM
VistaGen Therapeutics (1411685) Filer
Form DEF 14A
07/31/2026 3:11 PM
VistaGen Therapeutics (1411685) Filer
Form DEFA14A
07/31/2026 7:53 AM
VistaGen Therapeutics (1411685) Issuer
Williamson Douglas J (1911501) Reporting
Form 3
Initial statement of beneficial ownership of securities  
07/31/2026 7:56 AM
VistaGen Therapeutics (1411685) Issuer
Williamson Douglas J (1911501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/31/2026 7:48 AM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/02/2026 3:34 PM
Adler Reid G. (1924908) Reporting
VistaGen Therapeutics (1411685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2026 3:17 PM
Tressler Nick B. (1794362) Reporting
VistaGen Therapeutics (1411685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2026 7:28 AM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2026 4:13 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/15/2026 3:50 PM
VistaGen Therapeutics (1411685) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
06/15/2026 3:35 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/09/2026 4:04 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/19/2026 3:51 PM
Angelov Angel S (2132062) Reporting
VistaGen Therapeutics (1411685) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/19/2026 3:52 PM
Angelov Angel S (2132062) Reporting
VistaGen Therapeutics (1411685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 6:44 AM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/13/2026 4:27 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/09/2026 7:40 PM
Prince Joshua S. (1998663) Reporting
VistaGen Therapeutics (1411685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/09/2026 7:41 PM
Singh Shawn (1412071) Reporting
VistaGen Therapeutics (1411685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/09/2026 7:43 PM
Tressler Nick B. (1794362) Reporting
VistaGen Therapeutics (1411685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/09/2026 7:33 PM
Adler Reid G. (1924908) Reporting
VistaGen Therapeutics (1411685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/09/2026 7:38 PM
Cote Elissa S. (2069951) Reporting
VistaGen Therapeutics (1411685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 3:45 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/16/2026 3:10 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/11/2026 6:02 AM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/20/2026 8:12 AM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/17/2026 5:33 PM
ORBIMED ADVISORS LLC (1055951) Filed by
VistaGen Therapeutics (1411685) Subject
Form SCHEDULE 13G/A
02/17/2026 11:35 AM
JANUS HENDERSON GROUP PLC (1274173) Filed by
VistaGen Therapeutics (1411685) Subject
Form SCHEDULE 13G/A
02/06/2026 3:12 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/30/2026 1:47 PM
VANGUARD GROUP INC (102909) Filed by
VistaGen Therapeutics (1411685) Subject
Form SCHEDULE 13G/A
Buy Stocks… A Crash is Coming (Ad)

Think stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.tc pixel

See Jim Rickards' 2027 prediction before the November 30th deadline arrives.
01/09/2026 4:26 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/05/2026 7:51 PM
Prince Joshua S. (1998663) Reporting
VistaGen Therapeutics (1411685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2025 4:29 PM
VistaGen Therapeutics (1411685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/04/2025 5:05 AM
Tressler Nick B. (1794362) Reporting
VistaGen Therapeutics (1411685) Issuer
Form 3
Initial statement of beneficial ownership of securities  
12/04/2025 5:07 AM
Tressler Nick B. (1794362) Reporting
VistaGen Therapeutics (1411685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

VistaGen Therapeutics SEC Filings - Frequently Asked Questions

VistaGen Therapeutics (VTGN) has submitted 377+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

VistaGen Therapeutics's fiscal year ends on March 31. The company typically files its 10-K annual report by the end of May, covering the prior fiscal year's financial results. Key financial data from these reports is available on VistaGen Therapeutics's financial statements page.

The most recent filing was a Form 10-Q submitted on November 13, 2026. This was a quarterly financial update for 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:VTGN are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 11/13/2026. New filings are added as they're published.
From Our Partners